Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 4/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.31 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15441649 | 1.00 | CHRM1 (0.35) | CHRM1HRH3RORCRIPK2ACACB | |
| SCHEMBL15441641 | 0.91 | CHRM1 (0.36) | CHRM1HRH3RORCRIPK2ACACB | |
| SCHEMBL15420040 | 0.91 | CHRM1 (0.36) | CHRM1HRH3RORCRIPK2ACACB | |
| SCHEMBL15420067 | 0.91 | CHRM1 (0.36) | CHRM1HRH3RORCRIPK2ACACB | |
| SCHEMBL15420375 | 0.91 | CHRM1 (0.36) | CHRM1HRH3RORCRIPK2ACACB | |
| SCHEMBL15420400 | 0.91 | CHRM1 (0.36) | CHRM1HRH3RORCRIPK2ACACB | |
| SCHEMBL15441158 | 0.89 | KAT5 (0.38) | CHRM1HRH3RIPK2ACACBPDE1B | |
| SCHEMBL15420145 | 0.89 | KAT5 (0.38) | CHRM1HRH3RIPK2ACACBPDE1B | |
| SCHEMBL15420247 | 0.89 | MKNK1 (0.35) | CHRM1HRH3RIPK2ACACBPDE1B | |
| SCHEMBL15420726 | 0.88 | HRH3 (0.33) | CHRM1HRH3RIPK2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | CHRM1 227/4885HRH3 1365/4885RORC 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.